Byooviz Gains Interchangeability Status
The ranibizumab biosimilar was the first in ophthalmology to the US market in 2022, but its competition has already had a year of interchangeability exclusivity.
Source: ajmc.com
Beckerz Regeneron Eylea News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Beckerz Regeneron Eylea. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Beckerz Regeneron Eylea Today - Breaking & Trending Today